|Silence From Generex Broken With News of New Presentations|
|By Vinny Cassano|
|Thursday, 09 December 2010 00:00|
Generex Biotechnology Corp announced earlier in the week that positive data from the Phase II AE37 breast cancer vaccine trial will be presented at the 33rd annual San Antonio Breast Cancer Symposium.
The data slated for presentation confirm previously announced ascertations of the positive benefits of the AE37 , according to a press release issued on Monday by Generex, and offer a glimpse into the future potential of the Generex's pipeline of cancer vaccine products.
There's been little heard from Generex since the failed reverse split fiasco and at least an update on the cancer vaccine pipeline lets us know that the company still has a pulse, but let's not kid ourselves here, Oral-lyn is the short term catalyst for keeping this company alive and any update on when the trial will be considered complete or when results may be announced would be key.
The sheer potential of Oral-lyn on the market, if it makes it that far, has me inclined to add to my long position at the current prices on the basis of the potential risk/reward profile. Oral-lyn is a superior product to Mannkind's Afrezza, in my opinion, due to the fact that the insulin is absorbed through the inner lining of the cheek with Oral-lyn, whereas with Afrezza the insulin is absorbed through the lungs.vaccine
Afrezza will have a significant head start on the insulin spray market, however, if approved by the FDA later this month when it's expected that a decision will be rendered.
The Generex cancer vaccine pipeline, being developed by subsidiary Antigen Express, holds significant value, but all eyes are on the lookout for an Oral-lyn update at the present time.
Disclosure: Long GNBT.
Vinny also authors the popular stock investing blog VFC's Stock House.